Interpretation of Report on Cardiovascular Health and Diseases in China 2024

doi:10.12114/j.issn.1007-9572.2025.0199

Abstract

Abstract:

Cardiovascular diseases (CVD) and their risk factors are exerting an increasingly significant impact on public health, and the incidence rate of CVD continues to rise. The economic burden brought by CVD to residents and society is increasing, and it has become a major public health problem, and it is urgent to strengthen the government-led CVD prevention and control work. This article provides an interpretation of essentials from the newly published Report on Cardiovascular Health and Diseases in China (2024) , aiming to offer scientific evidence for CVD prevention, treatment, and the formulation of relevant policies.

Key words: Cardiovascular diseases, Epidemiology, Burden of disease, Risk factors, Prevalence, Mortality, Rehabilitation, Basic research, Medical device development, Expense

摘要：

心血管疾病（CVD）及其危险因素对居民健康的影响愈发显著，CVD的发病率仍持续升高。CVD给居民和社会带来的经济负担日渐加重，已成为重大的公共卫生问题，加强政府主导的CVD防治工作刻不容缓。本文对最新出版的《中国心血管健康与疾病报告2024》要点内容进行解读，以期为CVD防治和相关政策的制定提供科学依据。

关键词: 心血管疾病, 流行病学, 疾病负担, 危险因素, 患病率, 死亡率, 康复, 基础研究, 器械研发, 费用

CLC Number:

R154

LIU Mingbo,HE Xinye,YANG Xiaohong, et al. Interpretation of Report on Cardiovascular Health and Diseases in China 2024[J]. Chinese General Practice, 2025, 28(32): 3989-4008. DOI: 10.12114/j.issn.1007-9572.2025.0199.
刘明波,何新叶,杨晓红等. 《中国心血管健康与疾病报告2024》要点解读[J]. 中国全科医学, 2025, 28(32): 3989-4008. DOI: 10.12114/j.issn.1007-9572.2025.0199.

Figures/Tables 55

Figure 1 Incidence rate of cardiovascular and cerebrovascular diseases in Chinese residents（2023）

Figure 2 Incidence rate of cardiovascular and cerebrovascular events in Chinese residents by age（2023）

Figure 3 Mortality trends of major diseases among rural Chinese residents（2000-2021）

Figure 4 Mortality trends of major diseases among urban Chinese residents（2000-2021）

Figure 5 Cardiovascular disease mortality trends in urban and rural Chinese residents（2000-2021）

Figure 6 Proportion of major causes of death among rural Chinese residents（2021）

Figure 7 Proportion of major causes of death among urban Chinese residents（2021）

Figure 8 Age-standardized mortality rate of cardiovascular diseases in China（2005-2020）

Figure 9 Prevalence of coronary heart disease by gender and age

Figure 10 Incidence rate of acute myocardial infarction in Chinese residents（2023）

Figure 11 Incidence rate of acute myocardial infarction by age group（2023）

Figure 12 Coronary heart disease mortality by gender in urban and rural China（2021）

Figure 13 Trends in coronary heart disease mortality in urban and rural China（2002-2021）

Figure 14 Trends in acute myocardial infarction mortality in urban and rural China（2002-2021）

Figure 15 Stroke incidence rate among Chinese adults aged ≥18 years（2023）

Figure 16 Stroke incidence rate by age group in China（2023）

Figure 17 Cerebrovascular disease mortality by gender in urban and rural China（2021）

Figure 18 Age-specific mortality rate of cerebrovascular diseases by gender in urban China（2021）

Figure 19 Age-specific mortality rate of cerebrovascular diseases by gender in rural China（2021）

Figure 20 Food intake of Chinese residents by category（2015-2017）

Figure 21 Overweight，obesity，and central obesity rates by age and gender in China（2020-2022）

Figure 22 Trends in awareness，treatment，and control rates of hypertension among Chinese adults（2004-2018）

Figure 23 Serum levels of TC，TG，HDL-C and LDL-C in Chinese adults aged ≥18 years

Figure 24 Prevalence of dyslipidemia among Chinese adults（2002-2019）

Figure 25 Prevalence of dyslipidemia by gender and age

Figure 26 Trends in six major air pollutants in China（2013-2023）

Figure 27 Age distribution of hospitalized hypertension patients（2023）

Figure 28 Comorbidities among hospitalized hypertension Patients（2023）

Figure 29 Age distribution of hospitalized coronary heart disease patients

Figure 30 Proportion of primary discharge diagnoses for coronary heart disease patients

Figure 31 Types of interventional therapies among PCI-treated CHD patients

Figure 32 Volume of coronary interventions in China and ratio to CABG procedures

Figure 33 Composition of arrhythmia diagnoses among hospitalized patients（2023）

Figure 34 Proportion of different types of cardiac device implantations（2023）

Figure 35 Distribution of valvular heart disease types（2023）

Figure 36 Growth trends of TAVR vs. SAVR over the past 8 years

Figure 37 Proportion of mitral valve interventional procedure types

Figure 38 Age distribution of hospitalized heart failure patients

Figure 39 Volume of left ventricular assist device implantations in China（2017-2024）

Figure 40 Volume of heart transplantations in China（2015-2023）

Figure 41 Age distribution of congenital heart disease patients receiving surgical treatment

Figure 42 Disease type distribution among CHD patients receiving interventional therapy

Figure 43 Proportion of aortic disease types（2023）

Figure 44 Clinical classification of pulmonary hypertension（2023）

Figure 45 Composition of cardiomyopathy types

Figure 46 Cardiovascular comorbidities in obstructive sleep apnea patients

Figure 47 Proportion of kidney disease and renal replacement therapy in hospitalized CVD patients（2023）

Figure 48 Age distribution of hospitalized stroke patients

Figure 49 Discharges for cardio-cerebrovascular diseases in China（1980-2022）

Figure 50 Discharges for Cardio-Cerebrovascular Diseases and Diabetes in China（1980-2022）

Figure 51 Disease composition of total hospitalization costs for coronary heart disease（2023）

Figure 52 Composition of total hospitalization costs for cardiovascular diseases（2023）

Figure 53 Age distribution of treatment costs for cardiovascular disease patients（2023）

Figure 54 Cardiovascular disease share in medical expenditures by age group（2023）

Figure 55 Gender distribution of cardiovascular disease treatment costs（2023）

References 39

[1]	国家心血管病中心. 中国心血管健康与疾病报告2024[M]. 北京：中国协和医科大学出版社，2025.
[2]	盛百合，张馨予，杨洪喜，等. 中国居民1990-2019年心血管疾病和慢性呼吸系统疾病负担变化趋势及预测分析[J]. 中国公共卫生，2024，40(4)：477-483. DOI：10.11847/zgggws1142436.
[3]	国家卫生健康委员会，中国卫生健康统计年鉴2022[M]. 北京：中国协和医科大学出版社，2022.
[4]	WANG W, LIU Y N, LIU J M, et al. Mortality and years of life lost of cardiovascular diseases in China，2005-2020：Empirical evidence from national mortality surveillance system[J]. Int J Cardiol，2021，340：105-112. DOI：10.1016/j.ijcard.2021.08.034.
[5]	澎湃新闻. 控烟近20年，我国烟草产销量下降的拐点何时到来？[EB/OL]. （2024-08-28）[2024-08-30].
[6]	中国疾病预防控制中心. 2020年各地15岁及以上人群吸烟率数据图[EB/OL]. （2022-03-16）[2024-08-30].
[7]	ZENG X Y, LIU S W, XIAO L. Cigarette use and secondhand smoke exposure among secondary school students-China，2023[J]. China CDC Wkly，2024，6(22)：509-515. DOI：10.46234/ccdcw2024.098.
[8]	国家卫生健康委疾病预防控制局. 中国居民营养与慢性病报告（2020年）[M]. 北京：人民卫生出版社，2022.
[9]	赵丽云，丁钢强，赵文华. 2015-2017年中国居民营养与健康状况监测报告[M]. 北京：人民卫生出版社，2022.
[10]	YUAN X R, WEI Y L, JIANG H R, et al. Longitudinal relationship between the percentage of energy intake from macronutrients and overweight/obesity among Chinese adults from 1991 to 2018[J]. Nutrients，2024，16(5)：666. DOI：10.3390/nu16050666.
[11]	贾小芳，苏畅，何宇纳，等. 2022—2023年中国十省（自治区）成年居民宏量营养素摄入现状及食物来源[J].卫生研究，2024，53(6)：862-869，879. DOI：10.19813/j.cnki.weishengyanjiu.2024.06.002.
[12]	赵文华，李淑娟，杨振宇，等. 中国儿童营养与健康状况地图集[M]. 北京：中国地图出版社，2024.
[13]	王欢，张彦峰，武东明，等. 中国3~6岁幼儿中大强度身体活动、屏幕时间和睡眠时间达标率的空间分布特征和相关因素分析[J]. 体育科学，2023，43(1)：26-33. DOI：10.16469/j.css.202301003.
[14]	陈佩杰. 中国儿童青少年体育健身发展报告（2016）[M]. 北京：科学出版社，2018.
[15]	FAN X, CAO Z B. Physical activity among Chinese school-aged children：national prevalence estimates from the 2016 physical activity and fitness in China-the youth study[J]. J Sport Health Sci，2017，6(4)：388-394. DOI：10.1016/j.jshs.2017.09.006.
[16]	ZHU Z, TANG Y, ZHUANG J, et al. Physical activity，screen viewing time，and overweight/obesity among Chinese children and adolescents：an update from the 2017 physical activity and fitness in China-the youth study[J]. BMC Public Health，2019，19(1)：197. DOI：10.1186/s12889-019-6515-9.
[17]	GUO M M, KOH K T, WANG X Z. Trends of physical activity and recreational screen time among Chinese children and adolescents：a national study from 2017 to 2019[J]. BMC Public Health，2024，24(1)：1305. DOI：10.1186/s12889-024-18822-1.
[18]	XIN F, ZHU Z, CHEN S T, et al. Prevalence and correlates of meeting the muscle-strengthening exercise recommendations among Chinese children and adolescents：Results from 2019 Physical Activity and Fitness in China-The Youth Study[J]. J Sport Health Sci，2022，11(3)：358-366. DOI：10.1016/j.jshs.2021.09.010.
[19]	宋逸，罗冬梅，胡佩瑾，等. 1985—2014年中国汉族13~18岁中学生体质健康达标优秀率趋势分析[J]. 北京大学学报（医学版），2020，52(2)：317-322. DOI：10.19723/j.issn.1671-167x.2020.02.020.
[20]	董彦会，陈力，刘婕妤，等. 1985—2019年中国7~18岁儿童青少年超重与肥胖的流行趋势及预测研究[J]. 中华预防医学杂志，2023，57(4)：461-469. DOI：10.3760/cma.j.cn112150-20220906-00881.
[21]	WANG L M, ZHOU B, ZHAO Z P, et al. Body-mass index and obesity in urban and rural China：findings from consecutive nationally representative surveys during 2004-18[J]. Lancet，2021，398(10294)：53-63. DOI：10.1016/S0140-6736(21)00798-4.
[22]	LUO Y M, XIA F, YU X X, et al. Long-term trends and regional variations of hypertension incidence in China：a prospective cohort study from the China Health and Nutrition Survey，1991-2015[J]. BMJ Open，2021，11(1)：e042053. DOI：10.1136/bmjopen-2020-042053.
[23]	张梅，吴静，张笑，等. 2018年中国成年居民高血压患病与控制状况研究[J]. 中华流行病学杂志，2021，42(10)：1780-1789. DOI：10.3760/cma.j.cn112338-20210508-00379.
[24]	赵文华，张坚，由悦，等. 中国18岁及以上人群血脂异常流行特点研究[J]. 中华预防医学杂志，2005，39(5)：306-310. DOI：10.3760/j:issn:0253-9624.2005.05.004.
[25]	PAN L, YANG Z H, WU Y, et al. The prevalence，awareness，treatment and control of dyslipidemia among adults in China[J]. Atherosclerosis，2016，248：2-9. DOI：10.1016/j.atherosclerosis.2016.02.006.
[26]	戴璟，闵杰青，杨云娟. 中国九省市成年人血脂异常流行特点研究[J]. 中华高血压杂志，2019，27(3)：300. DOI：10.16439/j.cnki.1673-7245.2019.03.033.
[27]	国家卫生计生委疾病预防控制局. 中国居民营养与慢性病状况报告2015[M]. 北京：人民卫生出版社，2015.
[28]	李苏宁，张林峰，王馨，等. 2012—2015年我国≥35岁人群血脂异常状况调查[J]. 中国循环杂志，2019，34(7)：681-687.
[29]	LU Y, ZHANG H B, LU J P, et al. Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China[J]. JAMA Netw Open，2021，4(9)：e2127573.DOI：10.1001/jamanetworkopen.2021.27573.
[30]	WANG L M, PENG W, ZHAO Z P, et al. Prevalence and treatment of diabetes in China，2013-2018[J]. JAMA，2021，326(24)：2498-2506. DOI：10.1001/jama.2021.22208.
[31]	YANG C, WANG H B, ZHAO X J, et al. CKD in China：evolving spectrum and public health implications[J]. Am J Kidney Dis，2020，76(2)：258-264. DOI：10.1053/j.ajkd.2019.05.032.
[32]	ZHANG L X, ZHAO M H, ZUO L, et al. China kidney disease network（CK-NET）2016 annual data report[J]. Kidney Int Suppl，2020，10(2)：e97-185. DOI：10.1016/j.kisu.2020.09.001.
[33]	WANG L M, XU X, ZHANG M, et al. Prevalence of chronic kidney disease in China：results from the sixth China chronic disease and risk factor surveillance[J]. JAMA Intern Med，2023，183(4)：298-310. DOI：10.1001/jamainternmed.2022.6817.
[34]	ZHANG L X, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China：a cross-sectional survey[J]. Lancet，2012，379(9818)：815-822. DOI：10.1016/S0140-6736(12)60033-6.
[35]	CHEN P, LAM M I, SI T L, et al. The prevalence of poor sleep quality in the general population in China：a meta-analysis of epidemiological studies[J]. Eur Arch Psychiatry Clin Neurosci，2024，274(7)：1-14. DOI：10.1007/s00406-024-01764-5.
[36]	WANG D F, LI H L, ZHANG X T, et al. Changes and relevant factors in depressive and anxiety symptoms among Chinese adolescents after the "Double Reduction" policy：a repeated cross-sectional survey with a nested longitudinal subsample[J]. J Affect Disord，2024，367：88-95. DOI：10.1016/j.jad.2024.08.191.
[37]	LIANG F C, XIAO Q Y, HUANG K Y, et al. The 17-y spatiotemporal trend of PM_2.5 and its mortality burden in China[J]. Proc Natl Acad Sci USA，2020，117(41)：25601-25608. DOI：10.1073/pnas.1919641117.
[38]	MA G S, MEYER C L, JACKSON-MORRIS A, et al. The return on investment for the prevention and treatment of childhood and adolescent overweight and obesity in China：a modelling study[J]. Lancet Reg Health West Pac，2023，43：100977. DOI：10.1016/j.lanwpc.2023.100977.
[39]	LI J T, ZHAO D, CAI J, et al. Cost-effectiveness of treatment in adults with blood pressure of 130-139/80-89 mmHg and high cardiovascular risk in China：a modelling study[J]. Lancet Reg Health West Pac，2023，42：100962. DOI：10.1016/j.lanwpc.2023.100962.